Esperion Therapeutics, Inc. provided earnings guidance for the fourth quarter of 2021. For the fourth quarter of 2021 net U.S. product sales are expected to be between $12.0 to $12.5 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.25 USD | +0.45% | +5.63% | -24.75% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.75% | 424M | |
+42.83% | 748B | |
+34.11% | 598B | |
-5.70% | 356B | |
+18.06% | 325B | |
+4.63% | 283B | |
+17.02% | 245B | |
+9.26% | 211B | |
-4.21% | 209B | |
+2.43% | 166B |
- Stock Market
- Equities
- ESPR Stock
- News Esperion Therapeutics, Inc.
- Esperion Therapeutics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2021